Nautilus Biotechnology Q2 EPS $(0.14) Beats $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
Nautilus Biotechnology (NASDAQ:NAUT) reported a Q2 EPS of $(0.14), beating the analyst estimate of $(0.16) by 12.5%. This represents a 7.69% increase in losses compared to the same period last year.
July 30, 2024 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nautilus Biotechnology reported a Q2 EPS of $(0.14), beating the analyst estimate of $(0.16) by 12.5%. This is a positive surprise for investors, although the losses increased by 7.69% compared to the same period last year.
Beating EPS estimates is generally seen as a positive indicator for a company's stock price in the short term. Despite the increase in losses compared to last year, the market often reacts favorably to companies that exceed analyst expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100